168 filings
Page 5 of 9
8-K
yg0osb357
2 Nov 17
Third Quarter 2017 Investor Update
12:00am
8-K
f8xagfvsw
6 Sep 17
Ironwood Pharmaceuticals Announces Leadership Change
12:00am
8-K
qx6 klkhkc9pgcamk6z
3 Aug 17
Second Quarter 2017 Investor Update
12:00am
8-K
yc7cyr2vja8kydi
2 Jun 17
Submission of Matters to a Vote of Security Holders
12:00am
8-K
90vmlbe 6dl999rvoczq
8 May 17
First Quarter 2017 Investor Update
12:00am
8-K
ew5 9ho6elbqbb
18 Apr 17
Departure of Directors or Certain Officers
12:00am
8-K
18gi3qkk5uv 038sd
30 Mar 17
Entry into a Material Definitive Agreement
12:00am
8-K
scohtr7gs97
21 Feb 17
Fourth Quarter and Full Year 2016 Investor Update
12:00am
8-K
z9o 8ws9j
1 Feb 17
Entry into a Material Definitive Agreement
12:00am
8-K
403l5bgq wt
9 Jan 17
Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech
12:00am
8-K
j0zuu5pg9
5 Jan 17
Termination of a Material Definitive Agreement
12:00am
8-K
s0l6072nz qszpyq8s
4 Jan 17
Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors
12:00am
8-K
fawz5fmgnxz gqmk
3 Nov 16
Third Quarter 2016 Investor Update
12:00am
8-K
3uas4dpbhwd2sfsdwu
26 Sep 16
Ironwood Closes $150 Million Debt Refinancing
12:00am
8-K
sm1q aglk3gxe7
4 Aug 16
Second Quarter 2016 Investor Update
12:00am
8-K
nbxj7tcq3h bhwipwscv
3 Jun 16
Submission of Matters to a Vote of Security Holders
12:00am
8-K
bi37tifvinph5hsm
3 Jun 16
Ironwood Pharmaceuticals Closes U.S. Transaction with AstraZeneca for Lesinurad
12:00am
8-K
vbgrvyy 6es2y8g
9 May 16
First Quarter 2016 Investor Update
12:00am
8-K
vf3p c8athj1
26 Apr 16
Ironwood Pharmaceuticals Enters into U.S. Licensing Agreement with AstraZeneca for Lesinurad
12:00am
8-K
beqsufzp4ajr8tn54a25
7 Apr 16
Ironwood Pharmaceuticals Appoints Andrew Dreyfus to
12:00am